UNIGE document Scientific Article
previous document  unige:77510  next document
add to browser collection

An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes

Puddu, Alessandra
Nencioni, Alessio
Viviani, Giorgio Luciano
Published in Mediators of Inflammation. 2013, vol. 2013, p. 591056
Abstract Glucagon-like peptide-1 (GLP-1) is a gut hormone produced in the intestinal epithelial endocrine L cells by differential processing of the proglucagon gene. Released in response to the nutrient ingestion, GLP-1 plays an important role in maintaining glucose homeostasis. GLP-1 has been shown to regulate blood glucose levels by stimulating glucose-dependent insulin secretion and inhibiting glucagon secretion, gastric emptying, and food intake. These antidiabetic activities highlight GLP-1 as a potential therapeutic molecule in the clinical management of type 2 diabetes, (a disease characterized by progressive decline of beta-cell function and mass, increased insulin resistance, and final hyperglycemia). Since chronic hyperglycemia contributed to the acceleration of the formation of Advanced Glycation End-Products (AGEs, a heterogeneous group of compounds derived from the nonenzymatic reaction of reducing sugars with free amino groups of proteins implicated in vascular diabetic complications), the administration of GLP-1 might directly counteract diabetes pathophysiological processes (such as pancreatic β-cell dysfunction). This paper outlines evidence on the protective role of GLP-1 in preventing the deleterious effects mediated by AGEs in type 2 diabetes.
Keywords Diabetes Mellitus, Type 2/drug therapy/metabolismGlucagon-Like Peptide 1/metabolism/therapeutic useGlycosylation End Products, Advanced/metabolismHumansSignal Transduction/drug effects
PMID: 23365488
Full text
Article (Published version) (1.4 MB) - public document Free access
Research group L'athérosclérose et ses complications cliniques (591)
(ISO format)
PUDDU, Alessandra et al. An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes. In: Mediators of Inflammation, 2013, vol. 2013, p. 591056. doi: 10.1155/2013/591056 https://archive-ouverte.unige.ch/unige:77510

277 hits



Deposited on : 2015-11-23

Export document
Format :
Citation style :